Paul Barr, MD of University of Rochester, gives an overview of a clinical trial, Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, that was presented at the 58th ASH Annual Meeting in San Diego, CA.
Updated Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment in 65 Years and Older with CLL
